New Amsterdam Pharma
Helen Parker is a seasoned professional in the medical science liaison field, currently serving as a Senior Medical Science Liaison at NewAmsterdam Pharma since April 2024. Previous roles include Associate Director at Milestone Pharmaceuticals, Senior Medical Science Liaison at Relmada Therapeutics and BioXcel Therapeutics, and Director at Titan Pharmaceuticals. Helen's experience encompasses acting as a Medical Science Liaison at Aptevo Therapeutics and Braeburn, where responsibilities included engaging with key opinion leaders and healthcare professionals, presenting scientific data, and participating in training programs. Helen also served as a Cardiovascular Clinical Nurse Educator during a pivotal time for PCSK9 inhibitors and has a robust nursing background, holding positions in emergency care and clinical education. Educational qualifications include a Master's Degree as a Family Nurse Practitioner and a Bachelor's Degree in Nursing from Florida International University.
This person is not in the org chart
This person is not in any offices
New Amsterdam Pharma
1 followers
Founded in 2019 by the venture capital firm Forbion and John Kastelein, NewAmsterdam Pharma is a privately held, clinical-stage company focused on the research and development of transformative therapies for cardiometabolic diseases. Its mission is to improve patient care in populations where traditional therapies are not tolerated or have been unsuccessful.